GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » YoY Rev. per Sh. Growth

Consun Pharmaceutical Group (HKSE:01681) YoY Rev. per Sh. Growth : 5.93% (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Consun Pharmaceutical Group's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 was 5.93%.

Consun Pharmaceutical Group's Revenue per Share for the six months ended in Dec. 2024 was HK$2.13.


Consun Pharmaceutical Group YoY Rev. per Sh. Growth Historical Data

The historical data trend for Consun Pharmaceutical Group's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group YoY Rev. per Sh. Growth Chart

Consun Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.93 22.38 6.04 7.46 7.39

Consun Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.18 4.91 5.30 9.56 5.93

Consun Pharmaceutical Group YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Consun Pharmaceutical Group's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(3.807-3.545)/ | 3.545 |
=7.39 %

Consun Pharmaceutical Group's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2024 )
=(Revenue per Share (Q: Dec. 2024 )-Revenue per Share (Q: Dec. 2023 )) / | Revenue per Share (Q: Dec. 2023 )) |
=(2.125-2.006)/ | 2.006 |
=5.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Consun Pharmaceutical Group YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Consun Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
An Meng 2101 Beneficial owner
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Zhang Lihua 2202 Interest of your spouse
An Yubao 2101 Beneficial owner
Fmr Llc 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Gl China Long Equity Opportunities Fund Lp 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Double Grace International Limited 2101 Beneficial owner
Li Qian 2101 Beneficial owner
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group Headlines

No Headlines